Donidalorsen provides sustained HAE disease control: Trial data
Treatment with donidalorsen to prevent swelling attacks led to fewer of them and gains in quality of life for adults and teens with hereditary angioedema (HAE), according to final data from a Phase 3 trial and interim findings from its open-label extension study. The patients who switched from other prophylactic…